NRX-1074: Phase II data

A double-blind, U.S. Phase II trial in about 140 patients with MDD showed that a single dose of 10 mg IV NRX-1074 reduced mean HDRS-17 scores, the primary endpoint, by 14 points from baseline to 24 ho...